505 results on '"Walewski J"'
Search Results
2. Bereitstellung von 5G-Funktionalitäten für vernetzte Industrien und Automatisierung
3. ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
4. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study
5. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
6. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
7. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study
8. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA
9. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
10. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
11. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
12. Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL): 241
13. Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells
14. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
15. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL
16. TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES
17. INCIDENCE OF CLOSTRIDUM DIFFICILE ASSOCIATED INFECTION IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: PH-AB079
18. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) WITH OR WITHOUT TOTAL BODY IRRADIATION (TBI) IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL) PATIENTS. A RETROSPECTIVE EVALUATION OF 132 PATIENTS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG): PH-O113
19. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma
20. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant
21. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
22. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy
23. Soot visualisation by use of laser-induced soot vapourisation in combination with polarisation spectroscopy
24. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
25. Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the EBMT: O330
26. Ex vivo expanded human regulatory T-cells suppress B-cell lymphoma proliferation: O182
27. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
28. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group
29. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
30. Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma: Evaluation of safety and efficacy in a multicenter study
31. Atomic hydrogen concentration mapping in thermal plasma chemical vapour deposition
32. CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma
33. Treatment of Older Patients with Mantle-Cell Lymphoma
34. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) trial: 26
35. 6-year follow-up of the mint study suggests a role for radiotherapy to bulky disease: V648
36. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European mantle cell lymphoma network (MCL net): V116
37. Early or delayed administration of G-CSF after peripheral blood stem cell transplantation in lymphoma patients: P693
38. Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective cohort: V679
39. Rituximab added to CHOP-like chemotherapy improves the outcome of primary mediastinal large B-cell lymphoma (PMBCL) to the same extent as other diffuse large B-cell lymphoma (DLBCL): a subgroup analysis of MabThera International (MInT) Group: V300 - Best Abstract
40. 21. New Immunological Principles: 114 A NOVEL FULLY HUMAN ANTI-CD20 MONOCLONAL ANTIBODY. FIRST CLINICAL RESULTS FROM AN ONGOING PHASE I/II TRIAL IN PATIENTS WITH FOLLICULAR NONHODGKINʼS LYMPHOMA
41. 14. Clinical Results in Lymphoma I: 058 A RANDOMISED CONTROLLED TRIAL OF ABVD VS TWO MULTI-DRUG REGIMENS FOR ADVANCED HODGKIN LYMPHOMA – UPDATED RESULTS OF UKLG LY09
42. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
43. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study
44. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma
45. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
46. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R-CHOP AND WERE NOT CANDIDATES FOR HIGH-DOSE THERAPY AND ASCT - PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG-8)
47. PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL FEATURES AND OUTCOME IN 55 PATIENTS. POLISH LYMPHOMA RESEARCH GROUP STUDY
48. OUTCOME OF PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA WHO FAILED TO PROCEED TO OR RELAPSED AFTER HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION
49. MOLECULAR ANALYSES AND AN INNOVATIVE DIAGNOSTIC ALGORITHM IN MYC -NEGATIVE BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION: A SINGLE INSTITUTION EXPERIENCE
50. S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.